Nextcure reports third quarter 2020 financial results

Beltsville, md., nov. 05, 2020 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2020 financial results and provided a business update.
NXTC Ratings Summary
NXTC Quant Ranking